CMS has assigned a permanent J-code for Izervay for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Iveric Bio.
The new code for Izervay (avacincaptad pegol intravitreal solution) for geographic atrophy (GA), J2782, is effective April 1.
“Geographic atrophy is a progressive disease that can lead to irreversible vision loss, and early treatment can have a significant impact on patients’ lives,” Michael Petroutsas, head of U.S. commercial for Astellas Pharma, Iveric’s parent company, said in the release.